Q1 2018 Earnings Estimate for The Medicines Company Issued By Oppenheimer (MDCO)

The Medicines Company (NASDAQ:MDCO) – Research analysts at Oppenheimer dropped their Q1 2018 earnings per share estimates for shares of The Medicines in a research report issued on Monday, March 12th, Zacks Investment Research reports. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of ($0.64) for the quarter, down from their prior estimate of ($0.55). Oppenheimer has a “Buy” rating on the stock. Oppenheimer also issued estimates for The Medicines’ Q2 2018 earnings at ($0.63) EPS, Q3 2018 earnings at ($0.44) EPS, Q4 2018 earnings at ($0.45) EPS, FY2018 earnings at ($2.10) EPS, FY2019 earnings at ($2.20) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($1.44) EPS and FY2022 earnings at $0.93 EPS.

How to Become a New Pot Stock Millionaire

The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, February 21st. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.71). The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $20.71 million. During the same quarter last year, the business posted ($1.19) earnings per share. The company’s revenue for the quarter was down 50.6% on a year-over-year basis.

Several other equities research analysts also recently issued reports on MDCO. Zacks Investment Research downgraded shares of The Medicines from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Citigroup raised shares of The Medicines from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Monday, January 22nd. JPMorgan Chase reissued an “overweight” rating and issued a $45.00 price target on shares of The Medicines in a report on Wednesday, January 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $85.00 price target on shares of The Medicines in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $50.00.

NASDAQ:MDCO traded down $1.26 during mid-day trading on Wednesday, hitting $29.76. The stock had a trading volume of 988,616 shares, compared to its average volume of 1,171,874. The Medicines has a twelve month low of $24.45 and a twelve month high of $55.95. The company has a market capitalization of $2,273.25, a P/E ratio of -3.54 and a beta of 0.65. The company has a debt-to-equity ratio of 26.06, a quick ratio of 3.18 and a current ratio of 3.21.

In other The Medicines news, Director William Crouse sold 7,500 shares of the stock in a transaction dated Wednesday, March 21st. The shares were sold at an average price of $32.26, for a total value of $241,950.00. Following the transaction, the director now directly owns 60,633 shares of the company’s stock, valued at approximately $1,956,020.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.22% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in MDCO. Crossmark Global Holdings Inc. bought a new position in shares of The Medicines during the third quarter worth approximately $534,000. Swiss National Bank increased its holdings in shares of The Medicines by 1.6% during the third quarter. Swiss National Bank now owns 120,650 shares of the company’s stock worth $4,469,000 after purchasing an additional 1,900 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in shares of The Medicines by 13.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 102,000 shares of the company’s stock worth $3,778,000 after purchasing an additional 12,000 shares during the period. Municipal Employees Retirement System of Michigan increased its holdings in shares of The Medicines by 41.1% during the third quarter. Municipal Employees Retirement System of Michigan now owns 24,060 shares of the company’s stock worth $891,000 after purchasing an additional 7,010 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of The Medicines during the third quarter worth approximately $171,000.

TRADEMARK VIOLATION NOTICE: “Q1 2018 Earnings Estimate for The Medicines Company Issued By Oppenheimer (MDCO)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/brokers-offer-predictions-for-the-medicines-companys-q1-2018-earnings-mdco.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply